Health Care • Biotechnology: Pharmaceutical Preparations
$18.29 ▼ -0.35
(-1.88%)
MKT CAP: $926.4M • VOL: 2.23M
52W L $8 52W H $19
CYRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $176.2M | $156.8M | $168.7M |
| YoY Revenue Growth % | +12.4% | -7.1% | — |
| Gross Profit | $83.1M | $69.7M | — |
| Gross Margin % | 47.1% | 44.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$36.8M | -$121.7M | -$100.5M |
| Operating Margin % | -20.9% | -77.6% | -59.6% |
| Net Income (GAAP) | $78.3M | -$114.8M | -$99.6M |
| EBITDA (Normalized) | -$23.7M | -$107.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.6M | -$16.3M | -$757.0K |
| Capital Expenditures (CapEx) | $16.4M | $17.3M | — |
| Free Cash Flow (FCF) | -$25.0M | -$33.6M | -$757.0K |
| FCF Margin % | -14.2% | -21.4% | -0.4% |
| Return on Invested Capital (ROIC %) | -11.5% | -26.1% | — |
| Cash & Short-Term Equivalents | $250.5M | $34.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $502.6M | $401.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CYRX.